Oral selinexor-dexamethasone for triple-class refractory multiple myeloma

Autor: Chari, A. Vogl, D.T. Gavriatopoulou, M. Nooka, A.K. Yee, A.J. Huff, C.A. Moreau, P. Dingli, D. Cole, C. Lonial, S. Dimopoulos, M. Stewart, A.K. Richter, J. Vij, R. Tuchman, S. Raab, M.S. Weisel, K.C. Delforge, M. Cornell, R.F. Kaminetzky, D. Hoffman, J.E. Costa, L.J. Parker, T.L. Levy, M. Schreder, M. Meuleman, N. Frenzel, L. Mohty, M. Choquet, S. Schiller, G. Comenzo, R.L. Engelhardt, M. Illmer, T. Vlummens, P. Doyen, C. Facon, T. Karlin, L. Perrot, A. Podar, K. Kauffman, M.G. Shacham, S. Li, L. Tang, S. Picklesimer, C. Saint-Martin, J.-R. Crochiere, M. Chang, H. Parekh, S. Landesman, Y. Shah, J. Richardson, P.G. Jagannath, S.

BACKGROUND Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA trans

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::df356ee3e2755ac125003852f6a2a9dc
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3105737

A whole blood gene expression signature accurately diagnoses multiple myeloma and differentiates patients in remission from those with active and progressive disease

Autor: Schreder, M., Barrio, S. G., Drozdov, I., Matar, Samir, Herrmann, Ken, Einsele, H., Kidd, M., Modlin, I., Kortüm, K. M.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=unidue___bib::a750b63daccd529c9c9998343786307e

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

Autor: Ramos F., Maurillo L., Itzykson R., Bargay J., Stauder R., Venditti A., Seegers V., Gaidano G., Gardin C., Musto P., Greil R., Sánchez-Guijo F., Fenaux P., Thépot S., Récher C., Raffoux E., Quesnel B., Delaunay J., Cluzeau T., Koka A.M., Stamatoullas A., Chaury M.-P., Gyan E., Cheze S., Banos A., Morel P., Plantier I., Taksin A.-L., Shanti A., Sanhes L., De Botton S., Marolleau J.P., Pautas C., Wattel E., Isnard F., Guerci A., Vey N., Dreyfus F., Ifrah N., Ades L., Martínez-Robles V., Debén G., Garrido A., Casaño J., Salamero O., Bergua J.M., Colado E., García R., Pedro C., Redondo S., Tormo M., Bonanad S., Díez-Campelo M., Pérez-Encinas M., de la Fuente A., Xicoy B., Falantes J.F., Font P., González-López T.J., Martín-Núñez G., Montesinos P., Pleyer L., Burgstaller S., Schreder M., Tinchon C., Pfeilstoecker M., Steinkirchner S., Melchardt T., Mitrovic M., Girschikofsky M., Lang A., Krippl P., Sliwa T., Egle A., Linkesch W., Voskova D., Angermann H., Spagnoli A., Lunghi M., Pietrantuono G., Villani O.

Publikováno v: LEUKEMIA RESEARCH
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname

Hypomethylating agents are able to prolong the overall survival of some patients diagnosed with acute myeloid leukemia. The aim of this study was to evaluate the clinical use of azacitidine as front-line therapy in unfit acute myeloid leukemia (AML)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::590e2de10e9ad075961a7d9d5e48e32d
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924076153&doi=10.1016/j.leukres.2014.12.013&partnerID=40&md5=95d172f52911e7c83d24334fae23e084